Neurol. praxi. 2022;23(2):124-131 | DOI: 10.36290/neu.2022.022

Treatable lysosomal storage disorders with movement disorder manifestations

MUDr. Alexandra Lacková, doc. MUDr. Matej ©korvánek, PhD.
Neurologická klinika LF UPJ© a UNLP Koąice

Lysosomal storage disorders are a group of inherited metabolic disorders caused by mutations in genes encoding soluble lysosomal hydrolases, leading to the progressive accumulation of undegraded macromolecules in vital organs and tissues. Phenotypically, these disorders are characterised by a wide range of clinical symptoms with a combination of visceral, ocular, haematological, skeletal and neurological manifestations, with involvement of the extrapyramidal system being particularly common. Significant progress has been made in the treatment of these diseases in recent years, focusing on various innovative therapeutic approaches. The aim of this review is to focus on the clinical recognition of the most common lysosomal storage disorders with movement disorder manifestations (Gaucher disease, Niemann-Pick disease type C, Fabry disease, Tay-Sachs disease) and the current treatment options available.

Keywords: lysosomal storage disorders, movement disorders, neurodegeneration, parkinsonism, Gaucher disease, Niemann-Pick disease type C, Fabry disease, Tay-Sachs disease, enzyme replacement therapy, ERT, SRT.

Published: April 21, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lacková A, ©korvánek M. Treatable lysosomal storage disorders with movement disorder manifestations. Neurol. praxi. 2022;23(2):124-131. doi: 10.36290/neu.2022.022.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kingma SD, Bodamer OA, Wijburg FA. Epidemiology and diagnosis of lysosomal storage disorders; challenges of screening. Best Pract. Res. Clin. Endocrinol. Metab. 2015;29:145-157. Go to original source... Go to PubMed...
    2. Pastores GM, Maegawa GH. Clinical neurogenetics: neuropathic lysosomal storage disorders. Neurologic Clinics. 2013;31(4):1051-1071. Go to original source... Go to PubMed...
    3. Sun A. Lysosomal storage disease overview. Ann Transl Med. 2018;6(24):476. Go to original source... Go to PubMed...
    4. Hollak CE, Wijburg FA. Treatment of lysosomal storage disorders: successes and challenges. J Inherit Metab Dis. 2014;37(4):587-598. Go to original source... Go to PubMed...
    5. Stone WL, Basit H, Master SR. Gaucher Disease. 2021 Jul 26. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan. PMID: 28846219.
    6. Stirnemann J, Belmatoug N, Camou F, et al. A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments. Int J Mol Sci. 2017;18(2):441. Go to original source... Go to PubMed...
    7. Schiffmann R, Vellodi A. Neuronopathic Gaucher Disease. In Gaucher Disease; Futerman AH, Zimran A, Eds.; CRC Press Taylor & Francis: Boca Raton, FL, USA, 2007; pp. 175-196. Go to original source...
    8. Biegstraaten M, van Schaik IN, Aerts JMFG, et al. A monozygotic twin pair with highly discordant Gaucher phenotypes. Blood Cells Mol. Dis. 2011;46:39-41. Go to original source... Go to PubMed...
    9. Sidransky E, Lopez G. The Link between the GBA Gene and Parkinsonism. The Lancet Neurology. 2012;11(11):986-998. Go to original source... Go to PubMed...
    10. Malek N, Weil RS, Bresner C, et al. PRoBaND clinical consortium. Features of GBA-associated Parkinson's disease at presentation in the UK Tracking Parkinson's study. J Neurol Neurosurg Psychiatry. 2018;89(7):702-709. Go to original source... Go to PubMed...
    11. Lesage S, Anheim M, Condroyer C, et al. French Parkinson's Disease Genetics Study Group. Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease. Hum Mol Genet. 2011;20(1):202-210. Go to original source... Go to PubMed...
    12. Goker-Alpan O, Schiffmann R, LaMarca ME, et al. Parkinsonism among Gaucher disease carriers. J Med Genet. 2004;41(12):937-940. Go to original source... Go to PubMed...
    13. Chetrit EB, Alcalay RN, Steiner-Birmanns B, et al. Phenotype in patients with Gaucher disease and Parkinson disease. Blood Cells Mol Dis. 2013;50:218-221. Go to original source... Go to PubMed...
    14. Gupta N, Oppenheim I, Kauvar E, et al. Type 2 Gaucher disease: Phenotypic variation and genotypic heterogeneity. Blood Cells Mol Dis. 2011;46(1):75-84. Go to original source... Go to PubMed...
    15. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med. 2009;361(17):1651-1661. Go to original source... Go to PubMed...
    16. Vanier MT Niemann-Pick disease type C. Orphanet J Rare Dis. 2010;5:16. Go to original source... Go to PubMed...
    17. Poupetová H, Ledvinová J, Berná L, et al. The birth prevalence of lysosomal storage disorders in the Czech Republic: comparison with data in different populations. J Inherit Metab Dis. 2010;33(4):387-396. Go to original source... Go to PubMed...
    18. Kluenemann HH, Nutt JG, Davis MY, Bird TD. Parkinsonism syndrome in heterozygotes for niemann Pick C1. J Neurol Sci. 2013;335:219-220. Go to original source... Go to PubMed...
    19. Mengel E, Klünemann HH, Lourenço CM, et al. Niemann-Pick disease type C symptomatology: an expert-based clinical description. Orphanet J Rare Dis. 2013;8:166. Go to original source... Go to PubMed...
    20. Limphaibool N, Iwanowski P, Holstad MJV, Perkowska K. Parkinsonism in Inherited Metabolic Disorders: Key Considerations and Major Features. Front Neurol. 2018;9:857. Go to original source... Go to PubMed...
    21. Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30 Go to original source... Go to PubMed...
    22. Pineda M, Walterfang M, Patterson MC. Miglustat in Niemann-Pick disease type C patients: a review. Orphanet J Rare Dis. 2018;13(1):140. Go to original source... Go to PubMed...
    23. deVeber GA, Schwarting GA, Kolodny EH, Kowall NW. Fabry disease: immunocytochemical characterization of neuronal involvement. Ann Neurol. 1992;31:409-415. Go to original source... Go to PubMed...
    24. Löhle M, Hughes D, Milligan A, et al. Clinical prodromes of neurodegeneration in Anderson-Fabry disease. Neurology. 2015;84(14):1454-1464. Go to original source... Go to PubMed...
    25. Schaefer E, Mehta A, Gal A. Genotype and phenotype in Fabry disease: analysis of the Fabry Outcome Survey. Acta Paediatr Suppl. 2005;94:87-92; discussion 79. Go to original source...
    26. Wise AH, Yang A, Naik H, et al. Parkinson's disease prevalence in Fabry disease: A survey study. Mol Genet Metab Rep. 2018;14:27-30. Go to original source... Go to PubMed...
    27. Alcalay RN, Wolf P, Levy OA, et al. Alpha galactosidase A activity in Parkinson´s disease. Neurobiol Dis. 2018;112:85-90. Go to original source... Go to PubMed...
    28. Gago MF, Azevedo O, Guimarães A, et al. Parkinson's Disease and Fabry Disease: Clinical, Biochemical and Neuroimaging Analysis of Three Pedigrees. J Parkinsons Dis. 2020;10(1):141-152. Go to original source... Go to PubMed...
    29. Edelmann MJ, Maegawa GHB. CNS-Targeting Therapies for Lysosomal Storage Diseases: Current Advances and Challenges. Front Mol Biosci. 2020;7:559804. Go to original source... Go to PubMed...
    30. Solovyeva VV, Shaimardanova AA, Chulpanova DS, et al. New Approaches to Tay-Sachs Disease Therapy. Front Physi­ol. 2018;9:1663. Go to original source... Go to PubMed...
    31. Jahnová H, Poupětová H, Jirečková J, et al. Amyotrophy, cerebellar impairment and psychiatric disease are the main symptoms in a cohort of 14 Czech patients with the late-onset form of Tay-Sachs disease. J Neurol. 2019;266(8):1953-1959. Go to original source... Go to PubMed...
    32. Barritt AW, Anderson SJ, Leigh PN, Ridha BH. Late-onset Tay-Sachs disease. Pract Neurol. 2017;17(5):396-399. Go to original source... Go to PubMed...
    33. https://www.fabrydisease.org/index.php/component/content/article?id=126.
    34. https://dermnetnz.org/topics/fabry-disease/

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.